9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc. (NMTR) Stock Overview
Explore 9 Meters Biopharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1M
P/E Ratio
-0.02
EPS (TTM)
$-1.69
ROE
-2.07%
NMTR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of 9 Meters Biopharma, Inc. (NMTR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.02 and a market capitalization of 1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Bethany Sensenig
10
8480 Honeycutt Road, Raleigh, NC
2016